A prospective, multi center evaluation of the Bioliumus A9 eluting Axxess stent system in de novo coronary artery lesions. The study outcome will measure reduction in major adverse cardiac events compared to a historial control group.

Trial Profile

A prospective, multi center evaluation of the Bioliumus A9 eluting Axxess stent system in de novo coronary artery lesions. The study outcome will measure reduction in major adverse cardiac events compared to a historial control group.

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Umirolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Registrational; Therapeutic Use
  • Acronyms DIVERGE
  • Sponsors Devax
  • Most Recent Events

    • 23 May 2013 Long-term data were presented at EuroPCR 2013, according to a Biosensors International Group media release.
    • 30 May 2009 Results have been published in the March 23, 2009 issue of the Journal of the American College of Cardiology, according to a Devax media release.
    • 08 May 2009 New source identified and integrated (Australian New Zealand Clinical Trials Registry).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top